CSEMC Research Study Sample Clauses

CSEMC Research Study. CSEMC agrees to complete the CSEMC Research Study within approximately 24 months of the Effective Date in accordance with the protocol therefor. In the event that unexpected technical or regulatory difficulties makes completion of the CSEMC Research Study not achievable within this time period, CORAUTUS and CSEMC will renegotiate a replacement date in good faith. For the avoidance of doubt, if CSEMC is unable to meet this date, CORAUTUS will not be entitled to terminate the Agreement unless it can be demonstrated that CSEMC has not used good faith and reasonable efforts towards completion of the CSEMC Research Study. CSEMC shall provide CORAUTUS, promptly upon CORAUTUS’ request, with a full and complete copy of the CSEMC Research Study Data. In support of the Additional Clinical Trials sponsored by CORAUTUS and for the purpose of seeking Approval, CSEMC shall permit CORAUTUS to use, access and reference the CSEMC Research Study Data, and CSEMC will promptly advise the FDA in writing of such rights of reference and access when requested by CORAUTUS. To these ends, CSEMC will also, at Corautus expense upon CORAUTUS’ reasonable request make available its personnel involved in the CSEMC Research Study, to the extent such personnel are under the control of CSEMC, to answer questions about the CSEMC Research Study. The timing, duration and place of such availability, shall be mutually agreed by the parties in advance.